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AbstrAct
We have recently demonstrated a critical role for progranulin in bladder cancer. 
Progranulin contributes, as an autocrine growth factor, to the transformed phenotype 
by modulating Akt-and MAPK-driven motility, invasion and anchorage-independent 
growth. Progranulin also induces F-actin remodeling by interacting with the F-actin 
binding protein drebrin. In addition, progranulin is overexpressed in invasive bladder 
cancer compared to normal tissue controls, suggesting that progranulin might play 
a key role in driving the transition to the invasive phenotype of urothelial cancer.  
However, it is not established whether targeting progranulin could have therapeutic 
effects on bladder cancer. In this study, we stably depleted urothelial cancer cells 
of endogenous progranulin by shRNA approaches and determined that progranulin 
depletion severely inhibited the ability of tumorigenic urothelial cancer cells to migrate, 
invade and grow in anchorage-independency. We further demonstrate that progranulin 
expression is critical for tumor growth in vivo, in both xenograft and orthotopic tumor 
models. Notably, progranulin levels correlated with response to cisplatin treatment and 
were upregulated in bladder tumors. Our data indicate that progranulin may constitute 
a novel target for therapeutic intervention in bladder tumors. In addition, progranulin 
may serve as a novel biomarker for bladder cancer.
IntroductIon
Bladder cancer is a major epidemiological issue in the 
United States with 74,000 estimated new cases and 16,000 
estimated deaths in 2015 [1]. About 70% of early stages 
bladder tumors present as low-grade noninvasive papillary 
tumors (Ta stage). The remaining comprises tumors that 
have penetrated the basement membrane but not invaded 
the muscle layer of the bladder wall (T1 stage) and muscle-
invasive tumors (T2-T4 stages) [2]. While the prognosis for 
low-grade tumors is generally good, about 15% of these 
patients develop invasive disease. For invasive tumors the 
prognosis is much less favorable, with only 50% survival at 
5 years [3]. Invasive tumors are frequently associated with 
metastasis, which is associated with a 5 year survival rate of 
6% [3]. Compared to other cancers, bladder cancer has the 
highest cost per patients in the US due to disease prevalence 
and costs associated with long-term monitoring [4]. However, 
despite the significant clinical impact of bladder cancer, there 
is still an urgent need to discover novel predictor of disease 
progression and novel therapeutic targets. 
Progranulin, also known as proepithelin, PCDGF 
(PC-derived growth factor), granulin-epithelin precursor 
or acrogranin, is an evolutionary-conserved, secreted 
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glycoprotein containing 7 and a half granulin (GRN) 
repeats which plays an important role as a bona fide growth 
factor in cell proliferation, angiogenesis, wound healing and 
transformation in several cancer systems [5–7]. Progranulin 
binds to the basement membranes of endothelial cells via 
a direct physical interaction with perlecan [8], an heparan 
sulfate proteoglycan affecting various biological functions 
including tumor angiogenesis [9–12].
In addition, progranulin regulates inflammation and 
neurodegeneration [13], and has been causatively linked to 
the development of frontotemporal dementia (FTD).
We have recently established that progranulin plays 
a critical role in bladder cancer progression [14, 15]. 
Progranulin promotes motility and invasion of urothelial 
cancer cells through the activation of the Akt and MAPK 
pathways and MAPK-dependent activation of paxillin, 
which may regulate focal adhesion dynamics [14, 15]. 
In addition, progranulin regulates F-actin remodeling by 
interacting with the F-actin binding protein drebrin  [16– 18], 
which is critical for progranulin-dependent urothelial cancer 
cell motility and invasion [18]. Importantly, drebrin regulates 
tumor growth in vivo [18] and its expression levels correlate 
with bladder tumor progression [18].  Indeed, progranulin 
expression is upregulated in invasive bladder cancer 
tissues vis-à-vis non-neoplastic tissues and it is detectable 
in the urine [15]. Thus, progranulin may be critical for the 
transition to the invasive phenotype of bladder cancer and 
may serve as a novel biomarker for bladder cancer.
In spite of this emerging body of evidence pointing 
to a critical role of progranulin in bladder cancer, it is not 
yet established whether targeting progranulin could affect 
tumorigenicity of urothelial cancer cells. Here we show 
that stable progranulin depletion using small hairpin RNA 
(shRNA) interference severely inhibited motility, invasion 
and anchorage-independent growth of tumorigenic UMUC-
3 and T24T urothelial carcinoma-derived cells. In addition, 
progranulin targeting markedly reduced in vivo tumor growth 
of UMUC-3 cells in both orthoptopic and subcutaneous 
xenograft tumor models. Importantly, progranulin depletion 
sensitized urothelial cancer cells to cisplatin treatment, 
further proving a pro-survival function of progranulin. 
Finally, enhanced progranulin expression in a bladder 
cancer tissue microarray correlated with tumorigenicity. 
Collectively, these results suggest that progranulin may work 
as a novel therapeutic target for bladder cancer and could 
serve as novel biomarker for bladder cancer. 
results
Progranulin depletion inhibits motility of 
urothelial cancer cells
Given the critical role of progranulin in regulating 
motility and invasion of urothelial cancer cells [15, 18, 19], 
we stably depleted endogenous progranulin in UMUC-3 
and T24T urothelial cancer cells by transfecting expression 
plasmids expressing either a scrambled shRNA as control 
or a progranulin-specific shRNA. After selection, pools 
of UMUC-3 and T24T-transfected cells were tested by 
immunoblot for progranulin expression in both lysates and 
conditioned media [15, 18, 19]. The levels of progranulin 
secretion in media conditioned by UMUC- 3 (Figure 1A) 
or T24T (Figure 2A) transfected with the shPGRN 
plasmid were significantly (95%) reduced in both cell lines 
compared to parental (P) or scrambled-(Scr)-transfected 
cells. Progranulin depletion caused a robust inhibition 
(***P < 0.001) of the ability of UMUC- 3 (Figure 1B) and 
T24T (Figure 2B) cells to migrate. Importantly, motility 
was fully restored in UMUC-3/shPGRN by stimulation 
with nanomolar concentrations (~80 nM) of human 
recombinant progranulin (***P < 0.001, Figure 1B), 
thereby confirming that the inability of UMUC-3/
shPGRN cells to migrate was due to progranulin ablation. 
Progranulin-depleted UMUC-3 (Figure 1C) and T24T 
(Figure 2C) cells were also considerably inhibited in 
their ability to close a wound as assessed by a wound 
healing lateral motility assay [15, 18, 19]. It is important 
to mention that we previously demonstrated that the 
ability of progranulin to promote lateral motility (wound 
healing) can be separated from the capacity to induce cell 
proliferation as in fact we previously determined at the 
wound site similar levels of BrdU incorporation between 
motile and cells unable to fill the wound [19], ruling out 
that progranulin depletion may affect wound healing just 
by affecting cell proliferation. In addition, wound healing 
was assessed at either 6 or 16 hours when cell proliferation 
would not be a major contributing factor.
Progranulin depletion inhibits invasion and 
anchorage-independent growth 
Next, given the pro-motility activity of progranulin 
[15, 18, 19], we tested whether progranulin depletion 
would also affect the ability of urothelial cancer cells 
to invade through a 3D extracellular matrix. Thus, 
we used Matrigel-coated filters to examine invasive 
migration of progranulin-depleted UMUC-3 and T24T 
cells. Progranulin depletion significantly (***P < 0.001) 
affected the capacity of UMUC-3/shPGRN (Figure 3A) 
and T24T/shPGRN (Figure 4A) to invade as compared 
to parental and scrambled-transfected cells. Similarly to 
the migration assays, the invasive ability of UMUC- 3/
shPGRN cells was fully restored (***P < 0.001) by 
recombinant human progranulin (Figure 3A). Notably, 
both UMUC-3/shPGRN (Figure 3B) and T24T/shPGRN 
cells (Figure 4B) were significantly impaired in forming 
colonies in a soft-agar assay (***P < 0.001). 
As additional control, we generated progranulin-
depleted UMUC-3 cells by transfecting a second 
progranulin-specific shRNA plasmids and isolated another 
pool of UMUC-3 cells with considerable reduction of 
progranulin production (Figure 5A). These cells also 
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Figure 1: Progranulin depletion inhibits uMuc-3 urothelial cancer cell motility. (A) The generation of UMUC-3/shScr 
(scramble control) and UMUC-3/shPGRN cells has been described in Materials and Methods. The progranulin-specific shRNA was 
TI350373 (Origine). Progranulin expression in lysates and conditioned media from parental (P), control (Scr) or shRNA progranulin-
transfected (shPGRN) UMUC-3 cells was detected by immunoblot with anti-progranulin polyclonal antibodies. (b) Migration of the 
various UMUC-3 cell lines was performed using transwells as described in detail in Materials and Methods. Data are the average of three 
independent experiments run in duplicates ± SD. ***P < 0.001. Recombinant human progranulin was supplemented at 80 nM (c) The 
in vitro “wound healing” motility assay in UMUC-3 cells in either SFM or SFM supplemented with 1% FBS was performed as described 
in Materials and methods. Cells were analyzed with a cell live microscope using the Metamorph Image Acquisition and Analysis software 
(Universal Imaging) (×100). 10 fields/plate were examined. Pictures from representative fields are shown.
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Figure 2: Progranulin depletion inhibits t24t urothelial cancer cell motility. (A) The generation of T24T/shScr (scramble 
control) and T24T/shPGRN cells has been described in Materials and Methods. The progranulin-specific shRNA was TI350373 (Origine). 
Progranulin expression in lysates and conditioned media from parental (P), control (Scr) or shRNA progranulin-transfected (shPGRN) T24T 
cells was detected by immunoblot with anti-progranulin polyclonal antibodies. (b) Migration of the various T24T cell lines was performed 
using transwells as described in detail in Materials and Methods. Data are the average of three independent experiments run in duplicates 
± SD. ***P < 0.001. (c) The in vitro “wound healing” motility assay in T24T cells in either SFM or SFM supplemented with 1% FBS was 
performed as described in Materials and methods. Cells were analyzed with a cell live microscope using the Metamorph Image Acquisition 
and Analysis software (Universal Imaging) (×100). 10 fields/plate were examined. Pictures from representative fields are shown.
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exhibited reduced motility (Figure 5B) and significant 
inhibition (***P < 0.001) of anchorage-independent 
growth (Figure 5C).
Collectively, these results indicate that progranulin 
expression levels exert an important role in regulating 
motility, invasion and anchorage-independent growth of 
bladder cancer cells. 
Progranulin modulates in vivo tumor formation 
To extend the above in vitro finding into an 
in vivo setting, we generated tumor xenograft models 
and determined whether targeting progranulin could 
suppress the ability of UMUC-3 cells to form tumors. 
UMUC-3/shScr control and UMUC-3/shPGRN cells 
were implanted subcutaneously into the left and right 
flanks respectively of 6 week-old Rag2-/- mice which lack 
the ability to initiate V(D)J rearrangement, thus severely 
immunocompromised. Once tumors were established, 
tumor sizes were monitored until the largest tumor reached 
~5000 mm3 in size. Importantly, 70% of UMUC-3/shScr 
cells generated tumor xenografts (Figure 6A, 6B) in 
contrast to progranulin-depleted UMUC-3 cells of which 
only 12% generated xenografts with an average tumor 
volume significantly smaller than control (***P < 0.001, 
Figure 6A, 6B). To confirm that the tumor xenografts 
had reduced expression of progranulin, we performed 
immunofluorescence analysis on frozen sections of tumors 
after the animals were sacrificed. Indeed, progranulin 
levels were significantly depleted in the UMUC-3/
shPGRN xenografts (Figure 6C) compared to UMUC-3/
shScr control cells (Figure 6C). 
Figure 3: Progranulin targeting modulates invasion and anchorage-independent growth of uMuc-3 urothelial 
cancer cells. (A) Parental (P), shScr-transfected (Scr) control and Progranulin-depleted (shPGRN) UMUC-3 cells were assessed for 
invasive ability through Matrigel-coated transwells as described in Materials and Methods. Data are the average of three independent 
experiments ± SD. ***P < 0.001. Recombinant human progranulin was supplemented at 80 nM. (b) Anchorage-independent growth was 
measured by colony formation in soft-agar as previously described [18, 19, 49]. Colonies > 150 μM were counted. The experiment is the 
average of three independent experiments run in duplicates ± SD. ***P < 0.001.
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To further expand the above findings regarding the 
role of progranulin in bladder tumor formation in vivo, 
we generated orthotopic bladder cancer xenografts by 
injecting UMUC-3/shScr and UMUC-3/shPGRN into the 
bladder of immunocompromised mice under ultrasound 
guidance. We then assessed growth as previously described 
[20, 21]. After 20 days, tumors derived from UMUC-3/
shScr control cells reached an average of 200 mm3 of 
tumor volume (Figure 7A); in contrast, the progranulin 
depleted UMUC-3/shPGRN showed a significantly 
reduced tumor growth (***P < 0.001, Figure 7A). Given 
the marked inhibition in tumor growth of the progranulin-
depleted tumors, we checked by immunofluorescence 
the levels of the protein Ki67, a cellular marker strictly 
associated with proliferation, in frozen sections of 
the orthotopic bladder cancer xenografts. Ki67 was 
significantly reduced in UMUC-3/shPGRN xenografts 
(10% positive nuclei) compared to UMUC-3/shScr tissue 
control (47% positive nuclei) (Figure 7C) suggesting that 
progranulin depletion inhibits tumor proliferation in vivo. 
It is known that cancer cell motility and invasion 
require a change in cellular morphology associated with 
actin remodeling. Moreover, we have recently shown 
that exogenous stimulation of urothelial cancer cells 
with progranulin severely compromised the F-actin 
network of the cells [18]. Therefore, we examined the 
actin network of UMUC-3 orthotopic xenografts by 
staining frozen sections of the tumor tissue with the 
phallotoxin rhodamine-phalloidin. Notably, in UMUC-
3/shPGRN derived tissue we could notice an intact and 
well assembled F-actin network, which was severely 
disrupted in control tissue derived from UMUC-3/shScr 
xenografts (Figure 7B, arrows in Insets), confirming our 
previous results indicating that progranulin regulates 
invasion, motility and proliferation of cancer cells 
by modulating F-actin remodeling [18]. As a further 
control of the suppression of progranulin in our tumor 
xenograft model, we tested the levels of progranulin by 
immunofluorescence analysis in the tumor tissue. Indeed, 
progranulin immunostaining resulted markedly reduced 
Figure 4: Progranulin targeting modulates invasion and anchorage-independent growth of t24t urothelial cancer 
cells. (A) Parental (P), shScr-transfected (Scr) control and Progranulin-depleted (shPGRN) T24T cells were assessed for invasive ability 
through Matrigel-coated transwells as described in Materials and Methods. Data are the average of three independent experiments ± SD. 
***P < 0.001. (b) Anchorage-independent growth was measured by colony formation in soft-agar as described IN Materials and Methods. 
Colonies >150 μM were counted. The experiment is the average of three independent experiments run in duplicates ± SD. ***P < 0.001.
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Figure 5: Progranulin depletion inhibits uMuc-3 urothelial cancer cell motility and anchorage-independent growth. 
(A) The generation of UMUC-3/shScr (scramble control) and UMUC-3/shPGRN cells has been described in Materials and Methods. The 
progranulin-specific shRNA used here was TI350374 (Origine). Progranulin expression in lysates and conditioned media from parental (P), 
control (Scr) or shRNA progranulin-transfected (shPGRN) UMUC-3 cells was detected by immunoblot with anti-progranulin polyclonal 
antibodies. (b) The in vitro “wound healing” motility assay in UMUC-3 cells in either SFM or SFM supplemented with 1% FBS was 
performed as described in Materials and Methods. Cells were analyzed with a cell live microscope using the Metamorph Image Acquisition 
and Analysis software (Universal Imaging) (×100). 10 fields/plate were examined. Pictures from representative fields are shown. 
(c) Anchorage-independent growth was measured by colony formation in soft-agar as described in Materials and Methods. Colonies 
> 150 μM were counted. The experiment is the average of three independent experiments run in duplicates ± SD. ***P < 0.001. 
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in frozen sections of UMUC-3/ShPGRN orthotopic 
xenografts compared to control tumor tissue (Figure 7B). 
Significantly, tumor tissues derived from UMUC-3/shScr 
xenografts showed reduced expression of the epithelial 
marker E-cadherin (Figure 7D) and enhanced levels of the 
mesenchimal protein vimentin (Figure 7E) compared to 
UMUC-3/shPGRN orthotopic xenografts  suggesting that 
progranulin-associated tumorigenesis of UMUC-3 cells 
might be, at least in part, associated with an epithelial-
to-mesenchimal (EMT) transition [22], which is severely 
affected by progranulin depletion.
Collectively, these findings provide a strong 
evidence for an important role for progranulin in 
regulating bladder tumor formation in vivo.
Progranulin depletion sensitizes uMuc-3 cells to 
cisplatin treatment
One of the standard treatments for invasive bladder 
cancer is based on utilizating platinum-containing anti-
cancer drugs, such as cisplatin [23]. This chemotherapeutic 
agent binds to and causes cross-linking of DNA, which 
ultimately triggers DNA damage and apoptosis. Thus, we 
tested whether progranulin could contribute to regulate the 
sensitivity of invasive urothelial cancer cells to cisplatin 
treatment. UMUC-3/shScr and UMUC-3/shPGRN 
cells were grown in 1% serum supplemented with 1 or 
10 μM cisplatin. Suppression of progranulin expression 
significantly enhanced cisplatin-dependent cell death at 
both 1 (***P < 0.001, Figure 8A) and 10 μM (**P < 0.05, 
Figure 8A), as compared to controls (Figure 8A). We 
confirmed these results performing MTS assays in 
the presence of increasing concentrations of cisplatin. 
UMUC- 3/shPGRN cells showed an IC50 of 4.25 μM 
compared to UMUC-3/shScr cells, which had an IC50 
of 6.125 μM (Figure 8B). In addition cell survival was 
significantly decreased in UMUC-3/shPGRN compared 
to UMUC-3/shScr cells (***P < 0.001, Figure 8B) at all 
concentrations tested.
These results further strengthen the hypothesis that 
progranulin is a leading pro-survival factor in bladder 
cancer and suggest that targeting progranulin together with 
cisplatin could enhance therapeutic efficacy of cisplatin-
based therapy in invasive bladder tumors.
Progranulin expression in bladder cancer tissues
Next, we assessed progranulin expression in human 
bladder cancer and determined whether these changes 
could be a prognostic factor for tumor progression. 
We previously showed in a very limited number of 
urothelial carcinoma cases (n = 5) that progranulin levels 
were upregulated in invasive tumors [15]. To expand 
these findings, we utilized a human bladder tumor 
microarray containing 69 validated cases, including 
various types and different stages of bladder cancers. 
In normal bladder, progranulin was barely detectable 
(Figure 9A, 9B). In contrast, all malignant bladder tumors 
exhibited a markedly-increased progranulin expression 
(***P < 0.001, Figure 9A, 9B). The only exception 
was mucinous carcinoma where progranulin expression 
was at levels comparable to normal tissue. Progranulin 
upregulation was not statistically different between T1 
and T2-4 urothelial carcinoma tissues. Progranulin was 
Figure 6: stable depletion of endogenous progranulin in uMuc-3 urothelial cancer cells inhibits tumor xenograft 
growth. (A) Xenograft volume at day 52 of mice injected with UMUC-3/shScr (shScr) and UMUC-3/shPGRN (shPGRN). ***P < 0.001. 
(b) Representative macroscopic photograph of a mouse 53 days post injection with UMUC-3/shScr in the left flank and UMUC3-shPGRN 
cell in the right flank. (c) Tumors extracted from UMUC-3/shScr and UMUC-3/sh-PGRN injected mice were tested for progranulin 
expression by immunofluorescence analysis. Three-dimensional surface plots are indicative of progranulin expression levels of the relative 
fluorescence images. Bar = 5 µm.
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also overexpressed in metastatic bladder tissues indicating 
that progranulin expression levels might be associated to 
bladder cancer metastasis (***P < 0.001, Figure 9A, 9B). 
In order to include in this analysis low grade superficial 
urothelial carcinomas, we tested progranulin expression 
levels in archived paraffin-embedded tissues derived from 
4 non-invasive carcinoma in-situ (Tis), 4 non-invasive low 
grade papillary carcinomas (Ta), 4 non-invasive high grade 
papillary carcinomas (Ta) using as control normal and 
invasive high grade carcinoma tissues (n = 4). Progranulin 
expression levels were considerably up-regulated in 
non-invasive low grade papillary carcinomas (Ta) 
(***P < 0.001 compared to benign tissues, Figure 9C, 9D) 
and enhanced in both non-invasive high grade papillary 
carcinomas (Ta) and high grade carcinoma tissues 
(*P < 0.01 compared to benign tissues, Figure 9C, 9D). 
while in non-invasive carcinoma in-situ (Tis) progranulin 
expression was at levels comparable to benign tissues 
(Figure C, D). 
dIscussIon
Muscle-invasive bladder tumors are biologically 
heterogeneous with variable clinical progression and 
response to chemotherapy [24]. Radical cystectomy with 
perioperative cisplatin-based chemotherapy is the standard 
of care for muscle-invasive bladder cancers [24] but no 
substantial advances in therapy have been made since the 
introduction of cisplatin-based regimens [24]. Therefore, 
there is an urgent need to identify novel predictor of 
disease progression and novel therapeutic targets for 
invasive bladder cancer.
Figure 7: Progranulin regulates orthotopic bladder tumor formation. (A) Tumor volume at day 20 of mice (n = 22) injected 
orthotopically, under ultrasound guidance, with UMUC-3/shScr (shScr) and UMUC-3/shPGRN (shPGRN) cells. ***P < 0.001. (b) 
Immunofluorescence staining of progranulin (green signal) and actin (red signal) in frozen sections of UMUC-3/shScr and UMUC-3/
shPGRN orthotopic xenografts. The two insets represent relative magnified areas of the immunofluorescence pictures. White arrows point 
at the cortical actin fibers, which are disrupted in the presence of progranulin in the ShScr orthotopic tumors. (c–e) Immunostaining of 
Ki67, actin, E-cadherin and vimentin in frozen sections of the orthotopic tumors.  Nuclei: blue. Bar = 10 µm. 
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We have recently demonstrated that progranulin 
modulates as autocrine growth factor motility and invasion 
of urothelial cancer cells. In addition, progranulin is 
overexpressed in invasive bladder tumor tissues compared 
to normal control suggesting that progranulin may work as 
an important driver of bladder tumor progression.
In the present study, we stably depleted endogenous 
progranulin in tumorigenic UMUC-3 and T24T urothelial 
cancer cells by shRNA approaches and show that: 
a) Progranulin depletion severely inhibits urothelial 
cancer cell motility and invasion, which are restored by 
stimulation with recombinant progranulin. b) Progranulin 
targeting significantly diminished the ability of urothelial 
cancer cells to grow in anchorage-independency. c) 
Progranulin expression levels are critical for in vivo tumor 
growth. d) Progranulin depletion sensitizes UMUC-3 
cells to cisplatin treatment. e) Progranulin is upregulated 
in various bladder cancer–derived tissues compared to 
normal tissue controls. 
 Despite the important role that progranulin plays 
in bladder cancer, the mechanisms regulating progranulin 
action are still very poorly characterized. In addition, very 
few proteins that regulate the early stages of progranulin 
signaling from the plasma membrane have been so far 
identified. 
Previous studies have discovered proteins of 
~130 kDa as putative progranulin receptors [25, 26] and 
more recently, sortilin, a single-pass Type I transmembrane 
protein of the Vps10 family, has been identified in 
neuronal cells as a novel progranulin-interacting protein 
using membrane binding with alkaline phosphatase-
labeled progranulin [27] . However, sortilin acts as 
negative regulator of progranulin levels and signaling 
by targeting progranulin for lysosomal degradation 
[27]. Reduced progranulin levels are associated with 
frontotemporal dementia similarly to haploinsufficiency 
associated with progranulin gene mutations [28, 29] and 
targeted manipulation of the sortilin/progranulin axis 
rescues progranulin haploinsufficiency [30].
Accordingly, we have recently demonstrated that 
sortilin is expressed at very low levels in castration-
resistant PC3 and DU145 prostate cancer cells [31]. 
Restoring sortilin expression in these cells severely 
reduces progranulin levels and inhibits motility, invasion, 
proliferation and anchorage-independent growth [31]. 
Significantly, these results are recapitulated by targeting 
endogenous progranulin in PC3 and DU145 cells. 
Progranulin has been shown to bind TNF receptors 
1 and 2 and diminish TNF-dependent activation of 
MAPK (ERKs, p38 and JNK) by altering the TNF/TNFR 
interaction [32]. These results therefore do not support 
a role of TNFRs as bona fide progranulin receptor. In 
addition, in the presence of CpG-ONDs progranulin 
proteolytic fragments are soluble cofactors for Toll-like 
receptor 9 (TLR9) and regulate innate immunity [33]. 
Furthermore, Tropomyosin 3 has been discovered as a 
novel progranulin-interacting protein in hepatocellular 
carcinoma cells [34], but the biological significance of this 
interaction remains to be elucidated. 
We have recently characterized a novel 
interaction between progranulin and the F-actin-
binding protein drebrin [16, 17] and shown that drebrin 
is required for progranulin-induced activation of the 
Akt/MAPK pathways, regulates F-actin remodeling 
thereby modulating motility, invasion and anchorage-
independent growth of urothelial cancer cells [18]. In 
addition, drebrin regulates in vivo tumor growth and 
its expression is upregulated in several human bladders 
cancers, irrespective of their histopathology [18]. These 
results were here confirmed in orthotopic tumors where 
in UMUC-3/shPGRN-derived tissue we detected an intact 
and well-assembled F-actin network, which was severely 
disrupted in control tissue derived from UMUC-3/shScr 
xenografts.
Figure 8: Progranulin depletion sensitized uMuc-3 urothelial cancer cells to cisplatin treatment. (A–b) UMUC-3/shScr 
and UMUC-3/shPGRN were plated onto six-well plates at a density of 3.5 × 105 cells/well in 10% FBS-containing media. After 24 hours, 
cells were washed and transfer to 1% FBS-containing media with or without cisplatin at the concentrations of 1 μM and 10 μM. Cells were 
then counted after 24 hours as previously described [31, 49, 50]. Data are the average of 5 independent experiments run in duplicates ± SD. 
Groups were compared by ANOVA. *P < 0.05. **P < 0.01. ***P < 0.001. (B) Cell survival was assessed in 1% serum-containing media 
by MTS assays at cisplatin concentration of 1, 10 and 20 μM. ***P < 0.001.
Oncotarget39990www.impactjournals.com/oncotarget
However, as drebrin is not a trans-membrane protein 
[16–18], it is not likely the progranulin cell-surface 
receptor. Instead, we can speculate that drebrin might be 
recruited at early stages of progranulin internalization 
from the cell membrane as part of a signaling multi-protein 
complex, which would include the putative progranulin 
membrane receptor. 
We have also analyzed tissues derived from 
orthotopic xenografts for markers of the epithelial-to-
mesenchimal (EMT) transition, which is an integral part 
of the transforming process [22]. Significantly, tumor 
tissues derived from UMUC-3/shScr xenografts showed 
reduced expression of the epithelial marker E-cadherin 
and enhanced levels of the mesenchimal protein vimentin 
compared to UMUC-3/shPGRN orthotopic xenografts. 
These preliminary results would suggest that the role of 
progranulin in bladder cancer tumor formation might be, 
at least in part, associated with an EMT transition [22], 
which would be reversed by progranulin targeting in 
urothelial cancer cells. These results are consistent with 
very recent data demonstrating that in ovarian cancer 
progranulin promotes motility and invasion through EMT 
and the activation of cancer-associated fibroblasts [35].
Our results provide the first demonstration that 
progranulin targeting may work as a novel  therapeutic 
approach in bladder cancer extending previous results 
from breast carcinoma [36] and hepatocellular carcinoma-
derived cell lines [37] , where progranulin targeting by 
either antisense strategies [36] or inhibitory antibodies 
[37]  respectively inhibits tumorigenicity. 
Figure 9: Progranulin is upregulated in bladder cancer tissues. (A) Human bladder tumor microarray containing 69 validated 
cases of various types and stages of bladder cancers and normal bladder tissue controls. The panels show light micrographs outlining 
the expression of progranulin in different tumors as indicated. Progranulin is expressed at high levels in all cancers analyzed compared 
to the normal bladder except for the mucinous carcinoma. The arrows show areas of high staining for progranulin in the epithelial 
compartments of all cancer studied. (b) Quantification of progranulin staining levels was assessed using ImageJ software. All cases in 
the tissue microarray were analyzed and quantified. Briefly, the threshold of each image was adjusted in order to show only the specific 
staining. The background was removed and the data were quantified and plotted using SigmaPlot software. Student’s t-tests were run 
to determine statistical significance of each class of cancers compared to normal bladder. *P < 0.05; ***P < 0.001. Bars = 100 μm. 
(c) Additional progranulin IHC on archived bladder cancer tissue samples, which include low and high grade superficial papillary 
tumors (Ta) and CIS (Ti). These results complement the TMA analysis with a broader spectrum of various urothelial carcinoma stages 
(d) Progranulin expression in archived tissue samples was analyzed and quantified as described above. *P < 0.05; ***P < 0.001.
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The mechanisms by which progranulin modulates 
response to cisplatin are currently unknown. However, 
recent data in glioblastoma have demonstrated a role 
of progranulin in promoting Temozolomide resistance 
through the regulation of DNA repair and tumor cell 
stemness [38]. Future experiments will be devoted 
to characterize the role that progranulin may play in 
modulating DNA damage/repair in urothelial cancer cells. 
There is a great interest at the moment in the 
identification of novel biomarkers for prognosis and 
treatment selection of advanced bladder cancers [39–41]. 
Recent work has identified subtypes of muscle-invasive 
bladder tumors, basal, luminal and p53-like that resemble 
molecular subtypes of breast cancer [41–44]. The basal 
subtype shows more aggressive disease at presentation and 
is characterized by squamous differentiation. Significantly, 
progranulin levels are significantly upregulated in 
squamous cell carcinoma-derived tissues suggesting that 
progranulin levels may contribute with other markers 
[41–44] to the identification of different invasive subtypes 
of bladder tumors. 
Progranulin expression levels are not statistically 
different in low grade versus high grade urothelial 
carcinoma tissues. However, it is important to mention that 
the TMA we analyzed did not contain superficial papillary 
tumors (Ta) but only T1 tumors, which are low grade and 
not muscle-invasive but have penetrated the basement 
membrane [2], suggesting that progranulin expression 
might identify low grade tumors likely to progress to the 
muscle-invasive stage of urothelial carcinoma. The results 
of the additional analysis of progranulin expression in 
archived bladder cancer tissues for the most part confirms 
the TMA data and suggest high progranulin expression 
levels in both superficial and invasive tumors. Progranulin 
levels are instead low in carcinoma-in-situ samples at 
levels comparable to normal tissues. Collectively, these 
results are somewhat surprising considering the role 
of progranulin in motility and invasion and indicate 
the progranulin levels are predictive of bladder tumor 
formation but do not separate superficial from invasive 
tumors. Because we have recently shown that drebrin is 
instead highly expressed in high grade invasive tumors 
compared to low grade superficial and normal controls 
[18], these results might indicate that progranulin 
downstream effectors, such as drebrin or the unidentified 
progranulin receptor, are likely better predictor of tumor 
progression than progranulin itself.
Notably, progranulin expression levels are also 
upregulated in metastatic urothelial carcinoma-derived 
tissues compared to normal bladder tissue controls. These 
results would support the hypothesis that progranulin by 
enhancing urothelial cancer cell motility and invasion may 
be critical not only for the early stages of the metastatic 
cascade, invasion from the primary site, intravasation 
and extravasation, but also important when migrated 
tumor cells reach the secondary site of metastasis, where 
progranulin might work as contributing factor to the 
colonization process [45]. Experiments aiming at the 
characterization of progranulin action in the metastatic 
colonization process are currently under way. 
In summary, our studies have demonstrated a critical 
role for progranulin in regulating motility, invasion, 
anchorage-independent growth in vitro and tumor 
formation in vivo of urothelial cancer cells. In addition, 
progranulin sensitizes invasive bladder cancer cells to 
cisplatin treatment. Progranulin may constitute therefore a 
novel target for therapeutic intervention in bladder tumors. 
MAterIAls And Methods
cell lines
Urothelial carcinoma-derived human UMUC-3 cells 
were obtained by ATCC (Manassas, VA, USA). T24T 
cells (a kind gift from Dr. Dan Theodorescu, University of 
Colorado Cancer Center) are a more aggressive isogenic 
derivatives of T24 cells and grow in soft-agar, [46–48]. 
UMUC-3 cells were maintained in MEM with 
EARL medium with 10% fetal bovine serum (FBS), while 
T24T cells were maintained in DMEM/F12 medium 
supplemented with 10% fetal bovine serum (FBS). Serum-
free medium (SFM) is DMEM supplemented with 0.1% 
bovine serum albumin and 50 μg/ml of transferrin (Sigma-
Aldrich, St Louis, MO, USA).
Generation of progranulin-depleted uMuc-3 cells
UMUC-3 and T24T cells stably depleted of 
endogenous progranulin were generated by transfecting 
the pRS/shScr (scrambled shRNA) and pRS/shPGRN 
plasmids (OriGene Technologies, Inc.) using the TransIT®-
Prostate Transfection Kit (Mirus). 






Cells were selected in medium supplemented 
with 2 μg/ml of puromycin. After selection, pools of 
progranulin-depleted UMUC-3 and T24T cells were 
tested for progranulin expression levels in both lysates and 
conditioned media by immunoblot using anti-progranulin 
polyclonal antibodies (USBiologicals, Swampscott, MA, 
USA) as previously described [15, 31].
Migration, wound healing and invasion assays
HTS FluoroBloksTM inserts (Becton Dickinson, 
Durham, NC, USA) were saturated with PBS-1% bovine 
serum albumin for 2 hours at room temperature. Serum-
starved cells were labeled with DiI (Molecular Probes, 
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Grand Island, NY, USA) for 20 minutes at 37°C and then 
seeded in the HTS FluoroBloksTM upper chamber in either 
SFM or SFM supplemented with 1% FBS and incubated at 
37°C for 18 hours. After fixing in 4% paraformaldehyde, 
membranes were mounted on a slide and migrated cells 
were counted and photographed with a Zeiss Axiovert 
200 M cell live microscope at the Kimmel Cancer Center 
Confocal Microscopy Core Facility. 
Recombinant human progranulin was generated as 
previously described [8].
Wound healing was assessed in either SFM or 
SFM supplemented with 1% FBS by a scratch assay in 
monolayer has described in previous works from our 
laboratories [15, 31]. 
Cell invasion through a three-dimensional 
extracellular matrix was measured by a Matrigel 
invasion assay using BD Matrigel™ Invasion Chambers 
(BD Biocoat, Bedford, MA, USA) with 8.0 μm filter 
membranes. Cells (5 × 104) in 200 μl of SFM were plated 
onto each filter, and 750 µl of SFM or SFM supplemented 
with 1% FBS in the lower chamber. After 24 hours 
filters were washed, fixed, and stained with Coomassie 
Brilliant Blue. Cells on the upper surface of the filters 
were removed with cotton swabs. Cells that had invaded 
to the lower surface of the filter were counted under the 
microscope.
colony formation assay in soft-agar
Colony formation in soft-agar was performed as 
previously described [18, 19, 31, 49]. Cells were seeded 
in soft-agar at a density of 5 × 103 cells/35 mm plate and 
counted after three weeks in culture. Colonies > 150 μm 
were scored as positive.
bladder cancer xenografts
Experiments using 7- to 10-week-old Rag2–/–
mice were carried out according to protocols approved 
by the Institutional Review Board of Thomas Jefferson 
University. 4 × 106 UMUC-3/shScr (control) and 
shPGRN cells were injected subcutaneously in two 
distinct sites of mice flanks (control cells in the upper-
left flank and progranulin-depleted cells in the lower-right 
flank). Three independent experiments with 6 mice each 
were performed. Once tumors were established, tumor 
growth was measured every 2 days with a micro-caliper 
utilizing the following formula: V = a(b2/2), where a and 
b represent the larger and small diameters, respectively. 
When the largest tumor reached 5000 mm3 in size, mice 
were sacrificed and tumors were surgically dissected 
and divided. One half of each tumor was snap frozen in 
liquid nitrogen for further biochemical analysis, whereas 
the other half was embedded in OCT medium (Sakura 
Finetek, Torrance, CA, USA) and frozen at –20°C. 
8 µm thick cryostat sections were cut from the blocks, 
mounted on slides and subjected to immunofluorescence 
analysis utilizing a rabbit anti-progranulin antibody 
(Abcam, Cambridge, MA, USA). Three-dimensional 
surface plots were created with ImageJ and represent 
progranulin expression based on the intensity of the 
immunofluorescence signal.
orthotopic bladder cancer xenograft model. 
Orthotopic xenograft experiments were performed 
at the Vancouver Prostate Centre according to Canadian 
Council of Animal Care guidelines and approved by 
the Institutional Review Board of the University of 
British Columbia. Briefly, 22 nine weeks old female 
athymic nude mice (NU-Foxn1nu, Harlan Laboratories, 
Indianapolis, IN) with the average weight of 24.3 g were 
assigned into 2 groups by weight. Tumor inoculation was 
performed by ultrasound-guided injection according to 
the technique developed in our laboratories [20, 21]. Mice 
were anesthetized with 2.5% isoflurane plus meloxicam 
1 mg/ Kg (Boehringer Ingelheim Vetmedica, St. Joseph, 
MO) subcutaneously. Animals were placed one by 
one in supine position on the heated imaging platform 
(Vevo770, small animal imaging system, VisualSonics, 
Toronto, ON). After swabbing the lower abdomen with 
chlorhexidine 0.5%, application of sterile ultrasound gel 
and visualization of the bladder on the screen, bladder 
cancer cell suspension (50 μL of Matrigel with 104 cells, 
UMUC-3/shScr and UMUC-3/shPGRN) was injected into 
anterior bladder wall between its muscle layer and mucosa 
(30G ¾” needle and 1 mL syringe).
For in vivo tumor growth monitoring we used 
ultrasound 3D imaging and subsequent volume 
calculations starting on day 7 after tumor inoculation 
and then once weekly for 4 weeks total. Tumor take 
was 100%. All mice were euthanized (isoflurane 
anesthesia followed by CO2 asphyxiation) on day 26 
post-inoculation when some tumor volumes reached 
500 mm3 (10 mm in diameter). Bladders were then 
removed, drained from urine and weighed on analytical 
balance. Each tumor was divided in half; one part was 
snap frozen with liquid nitrogen and stored at −80ºC and 
the other kept in 10% buffered formalin for 24 hours and 
then stored in 70% isopropyl alcohol. 8 µm thick cryostat 
sections were cut from the frozen tissue once embedded 
in OCT, mounted on slides and further processed for 
immunofluorescence analysis utilizing a rabbit anti-ki67 
and a rabbit anti-granulin antibody (Abcam, Cambridge, 
MA, USA). Actin staining was obtained by incubation 
of the slides with rhodamine-phalloidin (Thermo 
Fisher, USA) according to the manufacturer’s protocol. 
E-cadherin and vimentin expression was detected using 
specific rabbit polyclonal antibodies (Cell Signaling, 
MA, USA) following by staining with Alexa-Fluor 
secondary antibody (Thermo Fisher Scientific, MA, 
USA).
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cell viability assay in the presence of cisplatin
UMUC-3/shScr and UMUC-3/shPGRN were plated 
onto six-well plates at a density of 3.5 × 105 cells/well in 
media supplemented with 10% FBS. After 24 hours, cells 
were washed twice with PBS 1× and transfer to 1% FBS-
supplemented media with or without cisplatin (Sigma-
Aldrich, St Louis, MO, USA) at the concentrations of 
1 μM and 10 μM. Cells were then counted after 24 hours 
in a boyden chamber.
Cell survival was additionally tested by MTS assays 
(Abcam) following the manufacturer’s instructions.
Immunohistochemical detection of progranulin 
expression in bladder cancer tissues
Progranulin expression was analyzed by 
immunohistochemistry on a Biomax (Rockville, MD, 
USA) human bladder cancer tissue microarray (BL208) 
at the Translational Core Facility of the Sidney Kimmel 
Cancer Center. The antibody used was an anti-granulin 
rabbit monoclonal antibody (Abcam, ab108608) at a 
dilution of 1:400. Detailed specifications of the bladder 
tissue array can be found at: http://www.biomax.us/tissue-
arrays/Bladder/BL208.
Archived paraffin-embedded tissues from 4 non-
invasive carcinoma in-situ (Tis), 4 non-invasive low 
grade papillary carcinomas (Ta), 4 non-invasive high 
grade papillary carcinomas (Ta) and control benign and 
invasive high grade carcinoma tissues (n = 4) were stained 
for progranulin expression as described above. All cases 
in the tissue microarray and from archived samples were 
analyzed for progranulin expression and quantified. 
Briefly, the threshold of each image was adjusted in 
order to show only progranulin-specific staining. The 
background was removed and the data were quantified and 
plotted using SigmaPlot software. Student’s t-tests were 
run to determine statistical significance of each class of 
cancers compared to normal bladder.
statistical analysis
Results of multiple experiments are expressed as 
mean ± SD. All statistical analyses were carried out with 
SigmaStat for Windows version 3.10 (Systat Software, 
Inc., Port Richmond, CA). Results were compared using 
the two-sided Student’s t test. Differences were considered 
statistically significant at P < 0.05.
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